抗哮喘药物的使用。他们影响运动性能吗?
文章的细节
-
引用
复制到剪贴板 -
惠誉KD
抗哮喘药物的使用。他们影响运动性能吗?
运动医学。1986;3 - 4月3 (2):136 - 50。
- PubMed ID
-
2870555 (在PubMed]
- 文摘
-
最近主要药理的发展管理哮喘患者提供了一个令人满意的药物控制哮喘。这些包括钠cromoglycate(色甘酸钠),H1-antagonists,颠茄生物碱、甲基黄嘌呤,糖皮质激素和β2-adrenoceptor兴奋剂。尽管大多数哮喘患者发展运动后支气管收缩的趋势,体育运动和体育活动现在接受宝贵的哮喘患者的整体管理。因此,控制运动性哮喘(EIA)是至关重要的,如果哮喘病患者安全地参与体育活动,在竞技体育没有呼吸的劣势。幸运的是,抑制或最小化的运动性哮喘可能实现在大多数哮喘患者运动前的气溶胶β2受体激动剂在必要时补充钠cromoglycate和/或茶碱。常规药物治疗要求达到和维持正常的通气功能在每一天的目标是所有哮喘患者和似乎是prerequisiste控制运动性哮喘。反兴奋剂控制引入高性能运动哮喘运动员提出了增加了困难。虽然不总是这样,目前的所有类药物前所述接受治疗哮喘和运动性哮喘。可能存在异常的禁止2β2-adrenoceptor受体激动剂,非诺特罗和奥西那林(异丙喘宁)。所有拟交感神经与α-胺或主要beta-stimulation是被禁止的。 The perpetuation of the need to report the use of beta 2-agonists prior to competition appears unnecessary. Although relatively little specific research has been undertaken, there is minimal evidence to suggest that asthmatics can derive any additional ergogenic advantage from medication to control asthma and exercise-induced asthma. beta 2-agonists, sodium cromoglycate and glucocorticoids administered by the aerosol route are not considered to be ergogenic. Some doubts have been raised concerning theophylline and its enhancement of both cardiac and respiratory muscle function. Investigations as to the validity of the suggestion that theophylline could augment physical performance appear warranted. It is reported that some athletes may be unnecessarily taking oral and perhaps parenteral glucocorticoids to obtain certain side effects. Any decision to ban these agents except for aerosol or local use could be supported.